	US 12,384,750 B2
	Ras inhibitors
Adrian L. Gill, Atherton, CA (US); James Cregg, Belmont, CA (US); Elena S. Koltun, Foster City, CA (US); and Yang Liu, Foster City, CA (US)
Assigned to Revolution Medicines, Inc., Redwood City, CA (US)
Filed by Revolution Medicines, Inc., Redwood City, CA (US)
Filed on Mar. 1, 2024, as Appl. No. 18/592,808.
Application 18/592,808 is a continuation of application No. 18/161,266, filed on Jan. 30, 2023, granted, now 11,952,352.
Application 18/161,266 is a continuation of application No. 17/089,035, filed on Nov. 4, 2020, granted, now 11,566,007, issued on Jan. 31, 2023.
Claims priority of provisional application 63/043,588, filed on Jun. 24, 2020.
Claims priority of provisional application 63/011,636, filed on Apr. 17, 2020.
Claims priority of provisional application 63/000,357, filed on Mar. 26, 2020.
Claims priority of provisional application 62/951,652, filed on Dec. 20, 2019.
Claims priority of provisional application 62/930,355, filed on Nov. 4, 2019.
Prior Publication US 2024/0400523 A1, Dec. 5, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/504 (2006.01); A61P 35/00 (2006.01); C07D 245/04 (2006.01)

CPC C07D 245/04 (2013.01) [A61P 35/00 (2018.01)]

8 Claims

1. A method of treating lung cancer in a subject in need thereof, wherein the lung cancer comprises a K-Ras G12C mutation, the method comprising administering to the subject a therapeutically effective amount of a compound having the following structure:

or a pharmaceutically acceptable salt thereof.